Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1038 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Huber expands Quincy facility

The expansion will be integrated into the existing HuberCal calcium carbonate milling operations and will increase GMP capabilities at the Quincy site. The Quincy calcium carbonate granulation manufacturing

FDA approves Perrigo Ketoconazole Foam, 2%

Perrigo’s Ketoconazole Foam, 2% is generic equivalent to Extina Ketoconazole Foam, 2%. Ketoconazole Foam, 2% is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years

Avantra renames to Courtagen

The company will continue to use the Avantra name for its proteomics portfolio, which includes the Avantra Biomarker System. Courtagen CEO Brian McKernan said the name change reflects

EMD Millipore takes over Amnis

EMD Millipore offers a range of performance products, services and business relationships that enable customers’ success in research, development and production of biotech and pharmaceutical drug therapies. With

FDA issues CRL for NuPathe Zelrix NDA

NP101 is an active, single-use, transdermal sumatriptan patch being developed for the acute treatment of migraine. The CRL includes chemistry, manufacturing and safety questions, which the company believes

DMV-Fonterra to acquire Brahmar Cellulose

Brahmar Cellulose develops, produces and markets microcrystalline cellulose (MCC) and sodium carboxyl methyl cellulose (SCMC) to the pharmaceutical industry world-wide. The transaction is expected to position DMV-Fonterra Excipients